Results 51 to 60 of about 1,204,710 (358)
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source
Progression-free survival in the ICON8 trial [PDF]
The Lancet, 2020 C. David Fuller +3 more
openaire +5 more sources
European Journal of Medical ResearchBackground Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options.
Elyar Mahboubi +3 more
doaj +1 more source
Multiple gene aberrations and breast cancer: lessons from super-responders. [PDF]
, 2015 BackgroundThe presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.Case presentationsWe performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone ...
Atkins, Johnique T +6 more
core +2 more sources
FEBS Letters, EarlyView.In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley +1 more source
Experimental Hematology & OncologyDiagnosis-to-treatment interval (DTI) is an important prognostic factor in patients with newly diagnosed aggressive lymphomas, however the impact of DTI on outcomes in marginal zone lymphoma (MZL) is unknown.
Narendranath Epperla +13 more
doaj +1 more source
Acta OncologicaBackground and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this ...
Lisa Millgård Sagberg +10 more
doaj +1 more source
Long Term Clinical Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Single Center Study [PDF]
The Korean Journal of Helicobacter and Upper Gastrointestinal ResearchObjectives Few studies have reported long-term follow-up after treatment of gastric mucosaassociated lymphoid tissue (MALT) lymphoma. In this single-center study, we investigated longterm treatment outcomes in patients diagnosed with gastric MALT ...
Seong Hyun Koh +6 more
doaj +1 more source
CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY [PDF]
International Journal of Technology Assessment in Health Care, 2018 Objectives:A primary outcome in oncology trials is overall survival (OS). However, to estimate OS accurately requires a sufficient number of patients to have died, which may take a long time. If an alternative end point is sufficiently highly correlated with OS, it can be used as a surrogate.
Hernandez-Villafuerte, K. +2 more
openaire +3 more sources
Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy [PDF]
, 2015 INTRODUCTION: Mutations (MT) of the KRAS gene are the most common mutation in non-small cell lung cancer (NSCLC), seen in about 20-25% of all adenocarcinomas. Effect of KRAS MT on response to cytotoxic chemotherapy is unclear.
Aggarwal, Charu +8 more
core +4 more sources